

Strategies for an HIV Cure 2016
November 14-16, 2016
Draft Agenda (Updated 11/1/2016)

Monday, November 14

7:00 am Registration and Poster Set Up

8:00 am **Welcome**

Karl Salzwedel, NIAID

8:10 am **Keynote:** Addressing HIV Persistence: A Novel Approach Involving $\alpha 4\beta 7$ Integrin

Anthony Fauci, Director, NIAID

Session 1: Martin Delaney Collaboratories for HIV Cure Research Overview

Chairs: Carl Dieffenbach, NIAID & Michael Lederman, Case Western Reserve University

8:45 am **BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication**

Overview

Douglas Nixon, George Washington University

Harnessing Cytotoxic T-Lymphocytes to Eliminate Intact and Defective Viral Reservoirs

R. Brad Jones, George Washington University

Directing Immune Effectors to Viral Sanctuaries in Lymphoid Tissues

Elizabeth Connick, University of Arizona

Cure Research Community Engagement Strategies

Manya Magnus, George Washington University

(Additional Panelists: *Tyson Evans, DC CARE and START at Westminster & Deborah Persaud, Johns Hopkins University*)

9:45 am Break (poster viewing & networking)

10:15 am **DARE: Delaney AIDS Research Enterprise to Cure HIV**

Overview of the Scientific Agenda

Steven Deeks, University of California, San Francisco

Breaching the B Follicular Sanctuary

Louis Picker, Oregon Health & Science University

Immune Checkpoint Blockade

Sharon Lewin, The Peter Doherty Institute for Infection and Immunity

Characterizing the Systemic Reservoir

Timothy Henrich, University of California San Francisco

(Additional Panelists: *Jeff Lifson, Frederick National Laboratory for Cancer Research & David Evans, Project Inform*)

11:15 am **defeatHIV: Delaney Cell and Genome Engineering Initiative**

Overall Scientific Strategy

Keith Jerome, Fred Hutchinson Cancer Research Center

Modeling Cell and Gene Therapy for HIV/AIDS in Nonhuman Primates

Hans-Peter Kiem, Fred Hutchinson Cancer Research Center

Constructing CAR T Cells as an Approach for HIV Therapy

Larry Corey, Fred Hutchinson Cancer Research Center

Paving the Road to Meaningful Engagement in HIV Cure Research

Michael Louella, University of Washington

(Additional Panelists: *Deborah Fuller, University of Washington & Chris Peterson, Fred Hutchinson Cancer Research Center*)

12:15 pm Lunch (on your own)

1:15 pm **Poster Session**

Session 2: Martin Delaney Collaboratories for HIV Cure Research Overview (continued)

Chairs: *Richard T. D'Aquila, Northwestern University & Satya Dandekar, University of California - Davis*

2:15 pm **BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy**

Goals & Clinical Studies

Luis Montaner, Wistar Institute

Clonal Expansion of Latently Infected Cells as a Barrier to Cure

Robert Siliciano, Johns Hopkins University

Antibody Therapeutics

Michel Nussenzweig, The Rockefeller University

Developing HIV-Resistant and HIV-Specific T Cells

James Riley, University of Pennsylvania

(Additional Panelists: *Pablo Tebas, University of Pennsylvania & David Metzger, University of Pennsylvania*)

3:15 pm Break (poster viewing & networking)

3:30 pm **CARE: Collaboratory of AIDS Researchers for Eradication**

Towards Effective Latency Reversal and Viral Clearance

David Margolis, University of North Carolina, Chapel Hill

Latency Reversal: Tools and Metrics

Daria Hazuda, Merck

Antibodies as Targeting Agents for HIV-Infected Cells

Barton Haynes, Duke University

Models for HIV Cure Research

Ann Chahroudi, Emory University

(Additional Panelists: *Nancie Archin, UNC Chapel Hill & Erik Valera, Latino Commission on AIDS*)

4:30 pm **I4C: Combined Immunologic Approaches to Cure HIV-1**

Overview

Dan Barouch, Beth Israel Deaconess Medical Center

Ad26/MVA Therapeutic Vaccination + TLR7 Stimulation in NHPs

Nelson Michael, US Military HIV Research Program

Clinical Trial Portfolio

John Mellors, University of Pittsburgh

Systems Serology to Define Immune Correlates of Viral Remission

Galit Alter, Ragon Institute

(Additional Panelists: *Jintanat Ananworanich, MHRP & Sherri Karas, U. Pittsburgh [CAB]*)

5:30 pm Adjourn for the Day

Tuesday, November 15

8:00 am Registration

8:30 am **Keynote:** Clinical Trials in HIV Cure: Where Have We Been, Where Should We Be Going?
Daniel Kuritzkes, Brigham and Women's Hospital

Session 3: Clinical Studies, Pediatrics, and Early Treatment

Chairs: Grace Aldrovandi, University of Southern California & Frank Maldarelli, NCI

9:00 am HIV Cure Research in the AIDS Clinical Trials Group (ACTG): Ongoing Studies and Opportunities for Collaboration
Joseph Eron, University of North Carolina, Chapel Hill
Rajesh Gandhi, Massachusetts General Hospital

9:30 am IMPAACT HIV Eradication Strategies for Pediatric Populations
Deborah Persaud, Johns Hopkins University

9:45 am Early Treatment Initiation and Treatment Interruption
Jintanat Ananworanich, US Military HIV Research Program

10:00 am Panel Discussion

10:15 am Break (poster viewing & networking)

Session 4: Community Engagement, Social Science, and Ethical Considerations for HIV Cure Research

Chairs: Amanda Castel, George Washington University & Dázon Dixon Diallo, SisterLove

10:45 am Beyond Reservoirs and Latency: Social and Behavioral Aspects of HIV Cure
Judith Auerbach, University of California, San Francisco

11:00 am The Power of the Cure: A Personal Perspective
Regan Hofmann, UNAIDS

11:15 am HIV Cure Studies: Risk, Risk Perception, and Ethics
Nir Eyal, Harvard University

11:30 am Crowdsourcing Contests and Community Engagement for HIV Cure Research: A Mixed Methods Evaluation
Allison Mathews, University of North Carolina, Chapel Hill

11:45 am Panel Discussion

12:00 pm Lunch (on your own)

1:00 pm **Poster Session**

Session 5: HIV Cure Basic Research

Chairs: Jonathan Karn, Case Western Reserve University & Ronald Swanstrom, University of North Carolina, Chapel Hill

2:00 pm **NCI HIV Dynamics and Replication Program**
Clones of HIV-Infected Cells Arise in Vivo in the First Few Weeks Following Infection
Stephen Hughes, NCI Center for Cancer Research

Characterizing the Transcriptional Activity of HIV Proviruses in Blood and Tissues Collected after Long-Term ART
Mary Kearney, NCI Center for Cancer Research

2:30 pm **NIAID Vaccine Research Center**

Understanding Mechanisms of HIV Persistence using Virus Sequence Analysis in HIV Controllers
Eli Boritz, NIAID Vaccine Research Center

Steady-State and Post-Vaccination TFH Dynamics in HIV Patients Treated with Combined Antiretroviral Therapy
Eirini Moysi, NIAID Vaccine Research Center

3:00 pm **Abstracts Selected for Oral Presentation**

Cells Containing Hypermutated HIV-1 Proviruses Can Be Preferentially Targeted by Cytotoxic T Lymphocytes
Ya-Chi Ho, Johns Hopkins University School of Medicine

The HIV-1 Antisense Transcript Ast Recruits the Polycomb Repressor Complex 2 to the HIV-1 5'LTR and Acts as a Viral Latency Factor
Fabio Romerio, University of Maryland School of Medicine

3:30 pm Break (poster viewing & networking)

Session 6: Preclinical HIV Cure Research

Chairs: Deborah Fuller, University of Washington & Jeffrey Lifson, Frederick National Laboratory for Cancer Research

4:00 pm **BIDMC/OHSU Consortium for Innovative AIDS Research (CIAR) in Nonhuman Primates**

Dan Barouch, Beth Israel Deaconess Medical Center
Louis Picker, Oregon Health & Science University

4:30 pm **Emory Consortium for Innovative AIDS Research (CIAR) in Nonhuman Primates**

Eric Hunter, Emory University
Rama Amara, Emory University

5:00 pm **amfAR HIV Cure Research Institute in San Francisco**

Structure, Directions and Partnerships
Paul Volberding, University of California, San Francisco

5:30 pm Adjourn for the Day

Wednesday, November 16

8:00 am Registration

8:30 am **Keynote:** Developing T cell Therapies for HIV: Lessons from Virus-Specific T Cell Therapies Post-Transplant
Catherine Bollard, Children's National Medical Center

Session 7: Beyond HAART: Innovative Approaches to Cure HIV-1

Chairs: Timothy Henrich, University of California, San Francisco and Christopher Peterson, Fred Hutchinson Cancer Research Center

9:00 am A Gene Therapeutic Approach to Stable Suppression of HIV-1 Replication
Ronald Desrosiers, University of Miami

9:30 am A Defend and Destroy Approach to Curing HIV
David Scadden, Massachusetts General Hospital

10:00 am Anti-HIV Gene Therapy: Defend and Attack
Irvin Chen, University of California, Los Angeles

10:30 am Break (poster viewing & networking)

- 11:00 am RNA-Directed Silencing and Excision of HIV-1 and CCR5
Kevin Morris, Beckman Research Institute of the City of Hope
- 11:30 am Engineering T cells to Provide Durable Control of HIV-1 Replication
James Riley, University of Pennsylvania
- 12:00 pm Next-Generation HSC Gene Therapy for HIV Control and Eradication
Paula Cannon, University of Southern California
Hans-Peter Kiem, Fred Hutchinson Cancer Research Center
- 12:30 pm **Closing Remarks**
Karl Salzwedel, NIAID
- 12:45 pm Adjourn Meeting

DRAFT